

ADDITIONAL FILE

One-carbon metabolism, cognitive impairment and CSF measures of Alzheimer pathology: Homocysteine and beyond

Loïc Dayon^{1, *}, Seu Ping Guiraud¹, John Corthésy¹, Laeticia Da Silva¹, Eugenia Migliavacca¹,
Domilė Tautvydaitė², Aikaterini Oikonomidi², Barbara Moullet², Hugues Henry³, Sylviane
Métairon¹, Julien Marquis¹, Patrick Descombes¹, Sebastiano Collino¹, François-Pierre J. Martin¹,
Ivan Montoliu¹, Martin Kussmann^{1, §}, Jérôme Wojcik⁴, Gene L. Bowman¹, and Julius Popp²

¹Nestlé Institute of Health Sciences, Lausanne, Switzerland

²CHUV, Old Age Psychiatry, Department of Psychiatry, Lausanne, Switzerland

³CHUV, Department of Laboratories, Lausanne, Switzerland

⁴Quartz Bio, Geneva, Switzerland

[§]Current affiliation: Liggins Institute, University of Auckland, New Zealand

Correspondence to: *Nestlé Institute of Health Sciences, EPFL Innovation Park, Bâtiment

H, 1015 Lausanne, Switzerland; Email: loic.dayon@rd.nestle.com, Phone: +41 21 632 6114, Fax:

+41 21 632 6499

Figure S1. Box-plots of CSF metabolite measurements for CDR = 0 and CDR > 0 (*i.e.*, CDR = 0.5 or 1). Level of significant is indicated as *p*-value after Bonferroni correction. Values were log-transformed.




Figure S2. Box-plots of plasma metabolite measurements for CDR = 0 and CDR > 0 (*i.e.*, CDR = 0.5 or 1). Level of significant is indicated as *p*-value after Bonferroni correction. Concentration values were log-transformed.




Figure S3. CSF and plasma metabolites correlated with CSF P-tau181 (a) and CSF tau (b) in APOE $\epsilon 4$ carriers ($n = 37$). Concentration values were log-transformed. Each dot represents a subject. The black line represents the linear fit and the gray shading its confidence interval.





Figure S4. Box-plots of plasma metabolite measurements in APOE $\epsilon 4$ carriers ($n = 37$) according to CSF P-tau181/A β 1-42 ratio, *i.e.*, “low” when P-tau181/A β 1-42 ≤ 0.0779 and “high” when P-tau181/A β 1-42 > 0.0779 for negative and positive CSF profiles of AD pathology respectively. Concentration values were log₁₀-transformed. Level of significant is indicated as p -value after Bonferroni correction.



SUPPLEMENTARY METHODS

Chemical reagents. LC-MS grade acetonitrile (CH₃CN), LC grade methanol (MeOH), formic acid (FA), trichloroacetic acid (TCA), perfluoroheptanoic acid (PFHA), ascorbic acid (AA), sodium hydroxide (NaOH) 0.1 M, hydrochloric acid (HCl), tris(2-carboxyethyl)phosphine (TCEP), dithiothreitol (DTT) and ammonium acetate (NH₄OAc) were purchased from Sigma-Aldrich (Buchs, Switzerland). Deionized water (H₂O) (18.2 MΩ·cm at 25 °C) was obtained from a Milli-Q apparatus (Millipore, Bedford, MA, USA). Homocysteic acid (HA), taurine, serine, cystine, glycine, homocystine (HCY2), riboflavin, methionine, pyridoxine, cystathionine, S-adenosylhomocysteine (SAH), pyridoxamine, S-adenosylmethionine (SAM), dimethylglycine (DMG), choline, betaine, 5-methyltetrahydrofolic acid (5-MTHF), taurine-¹³C₂, glycine-D₂, riboflavin-dioxypyrimidine-¹³C₄¹⁵N₂ and methionine-D₃ standards were purchased from Sigma-Aldrich. HA-D₄, serine-D₃, pyridoxine-D₂, cystathionine-D₄, SAM-D₄, DMG-D₆, choline-D₉, betaine-D₁₁ were purchased from CDN Isotopes (Pointe-Claire, Quebec, Canada). Cystine-D₄, HCY2-D₈ and pyridoxamine-D₃ were from Cambridge Isotopes Laboratories (Andover, M.A., USA) and SAH-D₄ was from Cayman Chemical (Ann Arbor, MI, USA). 5-MTHF-¹³C₅ was purchased from Merck (Schaffhausen, Switzerland).

Targeted metabolomics of the one-carbon cycle. Light and heavy standards were first dissolved individually in 0.1 M HCl (or in 0.1 M NaOH, 10 mmol·L⁻¹ NH₄OAc or in a mixture of MeOH/H₂O depending on their solubility). Calibration and internal standard (IS) solutions were prepared by dilution of the standard stock solutions in CH₃CN/H₂O (95%/5%). Calibration solutions were made according to the concentration ranges indicated in **Table 1** for each body fluid; they were freshly prepared with each batch of samples and injected at the beginning and the end of each batch. Quality controls (QCs) at two different concentrations were added to each sample

batch. Frozen samples were thawed out at room temperature and vortexed for 10 s. Volumes of 50 μL of CSF or plasma samples were transferred into 1.5 mL microcentrifuge tubes. A volume of 10 μL of IS solution was added to CSF or plasma, then 50 μL of a TCEP solution followed by 140 μL of MeOH with 1% FA. The tubes were vortexed for 15 min at 1400 rpm (4 °C) and centrifuged at 14500 rpm for 5 min. The supernatants were pipetted and filtered through a 0.22 μm filter before LC-MS/MS analysis. LC-MS/MS was performed with an Accela UHPLC 1250 Pump coupled to a TSQ Quantum Vantage triple quadrupole mass spectrometer equipped with a heated electrospray ionization (H-ESI) source (Thermo Scientific, San Jose, CA, USA). LC separation was performed using a gradient elution on a reversed-phase (RP) Acquity UPLC HSST3 1.8 μm , 100 \times 2.1 mm column (Waters, Milford, MA, USA) at a flow rate of 400 $\mu\text{L}\cdot\text{min}^{-1}$. Mobile phase A was H_2O containing 5 mM PFHA and mobile phase B was CH_3CN . The gradient profile was: (a) 0 min 95% A; (b) 0.5 min 95% A; (c) 8 min 5% A; (d) 10 min 5% A; (e) 11 min 95% A; (f) 13 min 95% A. The injection volume was 10 μL and the total run time was 13 min. MS detection was performed in positive electrospray ionization at unit resolution. Electrospray voltage, sheath gas, auxiliary gas, vaporizer temperature, and capillary temperature were respectively 4 kV, 10 arbitrary units, 5 arbitrary units, 200 °C and 350 °C. The collision gas (*i.e.*, argon) was set at 1.5 mTorr. Selected reaction monitoring (SRM) transitions have been described previously [23]. Automated tuned s-lens parameters were used and the scan time was set to 0.02 s. Xcalibur 2.1 software (Thermo Fisher Scientific) was used for instrument control, data acquisition and processing.

CSF A β 1-42, tau, and P-tau181. CSF A β 1-42, total-tau (tau), and tau phosphorylated at threonine 181 (P-tau181) concentrations were measured using commercially available ELISA kits (Fujirebio, Ghent, Belgium).

APOE genotyping. DNA was extracted from whole blood using the QIA Symphony DSP DNA Kit (Qiagen, Hombrechtikon, Switzerland). The SNV rs429358 and rs7412 were genotyped using the Taqman assays C___3084793_20 and C___904973_10 respectively (Thermo Fischer Scientific, Waltham, MA USA).

REFERENCES

23. Guiraud SP, Montoliu I, Da Silva L, Dayon L, Núñez Galindo A, Corthésy J, et al. High-throughput and simultaneous quantitative analysis of homocysteine–methionine cycle metabolites and co-factors in blood plasma and cerebrospinal fluid by isotope dilution LC–MS/MS. *Anal Bioanal Chem.* 2017;409:295-305.